SCHEMBL24371806

SCHEMBL24371806

COc1cc(C(C)C)ccc1C(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
ALDH1A1 P00352 6/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
POLB P06746 2/20 0.39
RECQL P46063 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HPGD P15428 1/20 0.38
GAA P10253 1/20 0.37
GFER P55789 1/20 0.37
ACHE P22303 2/20 0.36
BCHE P06276 1/20 0.36
TYR P14679 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TSHR P16473 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
ERN1 O75460 1/20 0.36
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24987670 0.86 GAA (0.42) HDAC4HDAC8POLBNPSR1GAA
SCHEMBL738832 0.86 HDAC4 (0.48) HDAC4HDAC8ALDH1A1SMN1; SMN2POLB
SCHEMBL19784261 0.82 HDAC4 (0.46) HDAC4HDAC8ALDH1A1SMN1; SMN2POLB
SCHEMBL10175139 0.79 HDAC4 (0.43) HDAC4HDAC8ALDH1A1SMN1; SMN2POLB
SCHEMBL84033 0.77 PPARG (0.53) HDAC4HDAC8ALDH1A1NPSR1HPGD
SCHEMBL8221532 0.76 HDAC4 (0.47) HDAC4HDAC8ALDH1A1SMN1; SMN2POLB
SCHEMBL11951653 0.76 HDAC4 (0.43) HDAC4HDAC8ALDH1A1SMN1; SMN2POLB
SCHEMBL16386815 0.76 PDE4A (0.44) HDAC4HDAC8ALDH1A1SMN1; SMN2POLB
SCHEMBL12180453 0.76 PDE4B (0.44) HDAC4HDAC8ALDH1A1SMN1; SMN2NPSR1
SCHEMBL26814968 0.75 LMNA (0.40) HDAC4HDAC8ALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY Lhotse Bio, Inc (US) 2024-01-18 US disclosed
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY Lhotse Bio, Inc (US) 2024-01-18 US disclosed
WO-2022083703-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LHOTSE BIO, INC. (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LPAR1, LPAR2, LPAR5 HDAC4 1370/4885HDAC8 650/4885ALDH1A1 1641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.